Gerald Simonneau

Summary

Country: France

Publications

  1. ncbi request reprint Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 126:35S-62S. 2004
  2. doi request reprint Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients
    Gerald Simonneau
    Service de Pneumologie, Hopital Universitaire de Bicetre, Universite Paris Sud, Le Kremlin Bicetre, France Electronic address
    Int J Cardiol 172:332-9. 2014
  3. ncbi request reprint Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
  4. ncbi request reprint Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
  5. ncbi request reprint Clinical classification of pulmonary hypertension
    Gerald Simonneau
    Department of Pulmonary and Critical Medicine, University of Paris Sud, Paris, France
    J Am Coll Cardiol 43:5S-12S. 2004
  6. doi request reprint Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
    David Launay
    Universite Paris Sud, Faculte de Medecine, Kremlin Bice tre, France
    Rheumatology (Oxford) 49:490-500. 2010
  7. pmc Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
  8. doi request reprint Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Chest 137:1297-303. 2010
  9. ncbi request reprint Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    N Engl J Med 351:1425-36. 2004
  10. doi request reprint Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Faculte de Medecine, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92140 Clamart, France
    Circulation 122:156-63. 2010

Detail Information

Publications106 found, 100 shown here

  1. ncbi request reprint Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 126:35S-62S. 2004
    ..Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center...
  2. doi request reprint Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients
    Gerald Simonneau
    Service de Pneumologie, Hopital Universitaire de Bicetre, Universite Paris Sud, Le Kremlin Bicetre, France Electronic address
    Int J Cardiol 172:332-9. 2014
    ..We report on the efficacy, safety, disease worsening, survival and prognostic factors in mildly symptomatic pulmonary arterial hypertension (PAH) patients treated with bosentan in the open-label extension phase of the EARLY study...
  3. ncbi request reprint Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
    ..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
  4. ncbi request reprint Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    ..Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension...
  5. ncbi request reprint Clinical classification of pulmonary hypertension
    Gerald Simonneau
    Department of Pulmonary and Critical Medicine, University of Paris Sud, Paris, France
    J Am Coll Cardiol 43:5S-12S. 2004
    ....
  6. doi request reprint Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
    David Launay
    Universite Paris Sud, Faculte de Medecine, Kremlin Bice tre, France
    Rheumatology (Oxford) 49:490-500. 2010
    ..We aimed to describe the long-term outcome of SSc-PAH treated with first-line monotherapy bosentan followed or not by the addition of prostanoids or sildenafil...
  7. pmc Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
    Barbara Girerd
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, F 94276, France
    Respir Res 11:73. 2010
    ..A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations...
  8. doi request reprint Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart, France
    Chest 137:1297-303. 2010
    ..Because they are generally excluded from randomized controlled trials, little is known about these patients...
  9. ncbi request reprint Treatment of pulmonary arterial hypertension
    Marc Humbert
    Centre des Maladies Vasculaires Pulmonaires, Unité Propre de Recherche de l Enseignement Supérieur EA2705, Hopital Antoine Beclere, Universite Paris Sud, Assistance Publique Hopitaux de Paris, Clamart, France
    N Engl J Med 351:1425-36. 2004
  10. doi request reprint Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, Faculte de Medecine, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, 92140 Clamart, France
    Circulation 122:156-63. 2010
    ..We conducted a study to characterize mortality in a multicenter prospective cohort of patients diagnosed with idiopathic, familial, or anorexigen-associated pulmonary arterial hypertension in the modern management era...
  11. doi request reprint Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation
    Barbara Girerd
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, 92140 Clamart, France
    Am J Respir Crit Care Med 181:851-61. 2010
    ..Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH)...
  12. ncbi request reprint Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension
    Hilario Nunes
    UPRES 2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Am J Respir Crit Care Med 167:1433-9. 2003
    ..These results suggest that patients with severe human immunodeficiency virus-associated PAH should be considered for long-term epoprostenol infusion in association with CART...
  13. ncbi request reprint [Pulmonary arterial hypertension]
    Xavier Jais
    Centre de référence de l hypertension pulmonaire sévère, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 92141 Clamart Cedex, France
    Rev Prat 58:1997-2010. 2008
    ..The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension...
  14. doi request reprint Pulmonary veno-occlusive disease: recent progress and current challenges
    David Montani
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, INSERM U999, Centre National de Référence de l Hypertension Pulmonaire Sévère, 92140 Clamart, France
    Respir Med 104:S23-32. 2010
    ..Unfortunately, the long term effects of these agents are variable and lung transplantation remains the treatment of choice...
  15. ncbi request reprint [Pulmonary hypertension associated with systemic sclerosis]
    Olivier Sanchez
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Ann Med Interne (Paris) 153:250-9. 2002
    ..Novel therapies including oral, sub-cutaneous or inhaled stable prostacyclin analogues and endothelin receptor antagonists are currently evaluated in large placebo-controlled trials...
  16. ncbi request reprint Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP Université Paris Sud, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur Heart J 27:589-95. 2006
    ..Data on long-term efficacy of bosentan in unselected idiopathic pulmonary arterial hypertension (IPAH) patients are lacking. We aimed to describe the long-term outcome of consecutive IPAH patients treated first-line with bosentan...
  17. doi request reprint HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
    Bruno Degano
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Clamart, France
    AIDS 24:67-75. 2010
    ....
  18. doi request reprint Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, F 94276, France
    Expert Opin Pharmacother 12:1585-96. 2011
    ..Therapeutic strategies that modulate the activity of endothelin are, therefore, of interest to improve the functional status of patients with PAH...
  19. doi request reprint Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial
    Xavier Jais
    Antoine Beclere Hospital, Clamart, France
    J Am Coll Cardiol 52:2127-34. 2008
    ..Our goal was to investigate the effect of treatment with the oral dual endothelin receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with chronic thromboembolic pulmonary hypertension (CTEPH)...
  20. doi request reprint Portopulmonary hypertension: survival and prognostic factors
    Jerome Le Pavec
    Universite Paris Sud 11, UPRES 2705, Service de Pneumologie, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 178:637-43. 2008
    ..Survival results in PoPH are contrasting, and prognostic factors need to be identified...
  21. doi request reprint Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicêtre F 94276, France
    Respir Med 104:S74-80. 2010
    ..This review details the rationale for the different combination strategies and examines the clinical evidence in favour of some of the approaches that have been evaluated...
  22. doi request reprint Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
    David Montani
    Universite Paris Sud, Orsay, France
    Adv Ther 26:813-25. 2009
    ..Due to their clinical effectiveness, tolerance profile, and their oral administration, sildenafil and tadalafil are two of the recommended first-line therapies for PAH patients in World Health Organization functional classes II or III...
  23. ncbi request reprint Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension
    Ségolène Cabrol
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie et Reanimation, AP HP, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Heart Lung Transplant 26:357-62. 2007
    ..Vascular remodeling lesions can be found in lungs of patients with CTEPH. Little is known about epoprostenol therapy in inoperable distal CTEPH patients...
  24. doi request reprint Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases
    Xavier Jais
    Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Arthritis Rheum 58:521-31. 2008
    ..To describe the response to first-line immunosuppressive therapy with or without pulmonary vasodilators in pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD)...
  25. ncbi request reprint Primary pulmonary hypertension: Current therapy
    Olivier Sitbon
    Service de Pneumologie et Reanimation Respiratoire, Pulmonary Vascular Center, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Prog Cardiovasc Dis 45:115-28. 2002
    ..In such patients with severe pulmonary hypertension refractory to medical therapy, atrioseptostomy and lung transplantation can be indicated...
  26. ncbi request reprint Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension
    Olivier Sanchez
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, Clamart, France
    Chest 130:182-9. 2006
    ..Immunosuppressive therapy should be better evaluated in this setting.Study design: Monocentric retrospective study...
  27. doi request reprint Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study
    Kristina Kemp
    Universite Paris Sud 11, Faculte de Medecine, Le Kremlin Bicetre, Clamart, France
    J Heart Lung Transplant 31:150-8. 2012
    ..Recent guidelines have proposed first-line combination therapy as a potential strategy for the treatment of functional class IV pulmonary arterial hypertension (PAH)...
  28. doi request reprint Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology
    David Montani
    Universite Paris Sud 11, UPRES EA 2705, Centre des Maladies Vasculaires Pulmonaires, Paris, France
    Medicine (Baltimore) 87:220-33. 2008
    ..Clinical outcomes of PVOD patients were worse than those of PAH patients...
  29. ncbi request reprint [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]
    Olivier Sitbon
    Centre de référence national de l HTAP, Service de Pneumologie, UPRES EA2705, Hopital Antoine Beclere, AP HP, Université Paris XI Sud, 92141 Clamart Cedex, France
    Rev Prat 58:2011-8. 2008
    ..However, their prognosis differs greatly: it is poor in scleroderma, and much better in congenital heart diseases...
  30. ncbi request reprint Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies
    Jerome Le Pavec
    Centre National de Référence del Histiocytose Langerhansienne, Univ Paris Diderot, Sorbonne Cité, Assistance Publique Hopitaux de Paris, Service de Pneumologie, Hopital Saint Louis, 75475 Paris Cedex 10, France
    Chest 142:1150-1157. 2012
    ..However, outcomes and efficacy of pulmonary arterial hypertension (PAH) therapies in patients with PH complicating PLCH(PLCH-PH) remain unknown...
  31. doi request reprint Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation
    Benjamin Sztrymf
    Universite Paris Sud 11, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 177:1377-83. 2008
    ..Germline mutations in the gene encoding for bone morphogenetic protein receptor 2 (BMPR2) are a cause of pulmonary arterial hypertension (PAH)...
  32. ncbi request reprint Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
    Olivier Sitbon
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, AP HP, Universite Paris Sud, Clamart, France
    Circulation 111:3105-11. 2005
    ..Characteristics of patients with idiopathic pulmonary arterial hypertension (IPAH) who benefit from long-term calcium channel blockers (CCB) are unknown...
  33. ncbi request reprint Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension
    Olivier Sitbon
    Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 170:1212-7. 2004
    ....
  34. ncbi request reprint An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation
    Xavier Jais
    UPRES EA 2705, Service de Pneumologie, Hopital Antoine Béclere AP HP, Universite Paris Sud, Clamart, France
    Hemoglobin 27:139-47. 2003
    ..This case ranks as one of the most severe examples ever recorded of the effect that splenectomy may have in DHS patients. Nonetheless, it represents the first case to receive a heart-lung transplant...
  35. doi request reprint Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary hypertension
    Denis Chemla
    Universite Paris Sud, Faculte de Medecine, EA4533, Le Kremlin Bicetre, France
    Chest 143:1343-50. 2013
    ..Our retrospective, high-fidelity pressure study tested the hypothesis that msePAP was proportional to mPAP, and looked at the implications for RVSW...
  36. doi request reprint Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival
    Marc Humbert
    Universite Paris Sud, Le Kremlin Bicetre, France AP HP Hôpital Antoine Béclère, Clamart, France
    Arthritis Rheum 63:3522-30. 2011
    ..However, little is known about the impact of detection programs on patients with SSc-PAH. This study was undertaken to assess the clinical characteristics of patients with SSc-PAH at diagnosis and their long-term outcomes...
  37. doi request reprint Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension
    Frederic Perros
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Institut Paris Sud Cytokines, Hopital Antoine Beclere, Universite Paris Sud 11, UPRES EA 2705, Clamart, France
    Am J Respir Crit Care Med 178:81-8. 2008
    ....
  38. doi request reprint Therapeutic advances in pulmonary arterial hypertension
    K Boutet
    Universite Paris Sud 11, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Ther Adv Respir Dis 2:249-65. 2008
    ..Despite those important advances there is still no cure for PAH. Fortunately, research is ongoing and many drugs show promises...
  39. doi request reprint Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences
    David Montani
    Universite Paris Sud 11, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Semin Respir Crit Care Med 30:411-20. 2009
    ..Lung transplantation remains the treatment of choice, but cautious use of specific PAH therapy can be helpful in select patients while awaiting this intervention...
  40. doi request reprint Updated clinical classification of pulmonary hypertension
    Gerald Simonneau
    Centre National de Référence des Maladies Vasculaires Pulmonaires, Universite Paris Sud, Hopital Antoine Beclere, Clamart, France
    J Am Coll Cardiol 54:S43-54. 2009
    ..Finally, it was decided to place pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis in a separate group, distinct from but very close to Group 1 (now called Group 1'). Thus, Group 1 of PAH is now more homogeneous...
  41. doi request reprint Pulmonary arterial hypertension in patients treated by dasatinib
    David Montani
    Univ Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Circulation 125:2128-37. 2012
    ..Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib...
  42. doi request reprint Ventilation/perfusion lung scan in pulmonary veno-occlusive disease
    Andrei Seferian
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Eur Respir J 40:75-83. 2012
    ..Future recommendations should be amended according to these results suggesting that V'/Q' lung scanning is not useful in discriminating PVOD from idiopathic PAH...
  43. doi request reprint Targeted therapies in pulmonary arterial hypertension
    David Montani
    Univ Paris Sud, Le Kremlin Bicetre, France AP HP, Service de Pneumologie, DHU Thorax Innovation, Hopital Bicetre, Le Kremlin Bicetre, France Inserm U999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France
    Pharmacol Ther 141:172-91. 2014
    ..In this summary, we review conventional therapy, pharmacological agents currently available for the treatment of PAH and the benefit/risk ratio of potential future therapies. ..
  44. doi request reprint Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension
    Marine Germain
    Unité Mixte de Recherche en Santé UMRS 937, Université Pierre and Marie Curie UPMC Université Paris 6 and Institut National de la Santé et de la Recherche Médicale INSERM, Paris, France
    Nat Genet 45:518-21. 2013
    ..97 (1.59-2.45; P = 7.47 × 10(-10)). CBLN2 is expressed in the lung, and its expression is higher in explanted lungs from individuals with PAH and in endothelial cells cultured from explanted PAH lungs...
  45. doi request reprint Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure
    Delphine Natali
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Chest 140:1066-8. 2011
    ..In this case report, we hypothesize that PTEN mutations may be a predisposing factor for the development of PAH, with anorexigen exposure as a potential trigger...
  46. ncbi request reprint Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study
    Olivier Sitbon
    Service de Pneumologie Réanimation Respiratoire, Hopital Antoine Beclere, 157, Avenue de la Porte Trivaux, F 92141 Clamart Cedex, France
    Chest 124:247-54. 2003
    ..We report on the long-term safety and efficacy of bosentan treatment in patients with pulmonary arterial hypertension (PAH)...
  47. doi request reprint Treatment of pulmonary arterial hypertension with targeted therapies
    Dermot S O'Callaghan
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicêtre F 94276, France
    Nat Rev Cardiol 8:526-38. 2011
    ..In this Review, we highlight the pharmacological agents currently available for the treatment of PAH and discuss potential novel strategies...
  48. ncbi request reprint Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Gastroenterology 130:120-6. 2006
    ..The aim of this study was to investigate the effect of beta-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving beta-blockers for the prophylaxis of variceal bleeding...
  49. doi request reprint Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults
    Denis Chemla
    Paris Sud University EA4046, Medical Intensive Care Unit, Paris, France
    Chest 135:760-8. 2009
    ..Our study evaluated the accuracy and precision of various empirical formulas relating mPAP and sPAP in resting adults...
  50. ncbi request reprint The CX3C chemokine fractalkine in allergic asthma and rhinitis
    Anne Cécile Rimaniol
    Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Allergy Clin Immunol 112:1139-46. 2003
    ..Because of its dual activity, fractalkine plays a major role in the transendothelial and transepithelial migration of leukocytes during inflammation...
  51. ncbi request reprint Pulmonary arterial hypertension in France: results from a national registry
    Marc Humbert
    UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Am J Respir Crit Care Med 173:1023-30. 2006
    ..Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in a shared-care approach...
  52. ncbi request reprint Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
    Olivier Sitbon
    Service de Pneumologie et Reanimation, UPRES EA 2705 on Pulmonary Vascular Diseases, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Am Coll Cardiol 40:780-8. 2002
    ..We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion...
  53. ncbi request reprint Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study
    Dominique Musset
    Service de Radiologie, Hôpital Universitaire Antoine Béclère, Clamart, France
    Lancet 360:1914-20. 2002
    ..The main aim was to assess the safety of withholding anticoagulant treatment in patients with low or intermediate clinical probability of PE and negative findings on spiral CT and ultrasonography...
  54. ncbi request reprint Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
    Steeve Provencher
    Service de Pneumologie et Réanimation Hôpital Antoine Béclère, Centre des Maladies Vasculaires Pulmonaires UPRES EA 2705, AP HP Université Paris Sud, Clamart, France
    Expert Opin Pharmacother 6:1337-48. 2005
    ..In the present report, the pharmacology, clinical efficacy and safety profile of bosentan are summarised. The place of bosentan among the current therapies available for the treatment of PAH is also discussed...
  55. ncbi request reprint Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
    Gerald Simonneau
    National Reference Center for Pulmonary Hypertension South Paris University, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, France
    Eur Respir J 40:874-80. 2012
    ..Selexipag was well tolerated with a safety profile in line with the expected pharmacological effect. Our results encourage the further investigation of selexipag for the treatment of PAH...
  56. pmc Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension
    Peter Dorfmuller
    Universite Paris Sud, Faculte de Medecine, Kremlin Bicetre, F 94276, France
    Respir Res 12:119. 2011
    ..The impact of OS on vascular remodeling in PH is still to be determined. We hypothesized, that augmented blood-flow could increase OS and might thereby contribute to DC/inflammatory cell-recruitment and smooth-muscle-cell-proliferation...
  57. ncbi request reprint Idiopathic pulmonary hypertension: what did we learn from genes?
    Benjamin Sztrymf
    UPRES 2705, Service de Pneumologie et Reanimation Respiratoire, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Sarcoidosis Vasc Diffuse Lung Dis 22:S91-100. 2005
    ..Nevertheless, PAH pathobiology remains unclear and genomic approaches may identify additional molecular determinants for this disorder...
  58. doi request reprint Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients
    Elie Fadel
    Department of Thoracic and Vascular Surgery and Heart Lung Transplantation, Hopital Marie Lannelongue, Le Plessis Robinson, Paris Sud University, Paris, France
    Eur J Cardiothorac Surg 38:277-84. 2010
    ..At our institution, patients with severe right ventricular dysfunction or congenital systemic-to-pulmonary shunt (CSPS) are preferentially treated with HLT. We sought to determine whether the outcomes warrant continuing this policy...
  59. ncbi request reprint Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature
    David Launay
    Centre National de Référence de l Hypertension Artérielle Pulmonaire, UPRES EA2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud 11, Clamart, France
    Medicine (Baltimore) 86:299-315. 2007
    ..In conclusion, this report underlines the rarity and severity of PAH in pSS patients. The best therapeutic regimen remains to be defined but should include standard PAH therapy and/or immunosuppressants...
  60. doi request reprint Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases?
    Dermot S O'Callaghan
    Faculte de Medecine, Universite Paris Sud, 94276 Kremlin Bicêtre, France
    Presse Med 40:e65-78. 2011
    ..This review summarises the epidemiologic, clinico-pathologic and imaging characteristics of PVOD in the setting of CTD and discusses potential management approaches...
  61. doi request reprint Retrospective institutional study of 31 patients treated for pulmonary artery sarcoma
    Sacha Mussot
    Department of Thoracic and Vascular Surgery and Heart Lung Transplantation, Marie Lannelongue Hospital, Paris Sud University, Le Plessis Robinson, France
    Eur J Cardiothorac Surg 43:787-93. 2013
    ..The study aimed to determine the optimal surgical procedure to treat pulmonary artery sarcomas responsible for pulmonary hypertension...
  62. doi request reprint Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension
    Pierantonio Laveneziana
    Departementde Physiologie, Faculte de MedecinePierre et Marie Curie, Site Pitié Salpêtrière, Paris, France
    Eur Respir J 41:578-87. 2013
    ..We conclude that DH-induced mechanical constraints and excessive ventilatory demand occurred in these young nonsmoking PAH patients with no spirometric obstruction and was associated with exertional dyspnoea...
  63. doi request reprint Renal replacement therapy in patients with severe precapillary pulmonary hypertension with acute right heart failure
    Benjamin Sztrymf
    Réanimation Médicale, Hopital Antoine Beclere, AP HP, Clamart, France
    Respiration 85:464-70. 2013
    ..Renal replacement therapy has been suggested as a therapeutic option in the setting of acute right ventricular failure in patients with severe precapillary pulmonary hypertension. However, there are few data supporting this strategy...
  64. ncbi request reprint Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Cardiovasc Pharmacol 49:1-5. 2007
    ..Selected patients with PAH can be safely transitioned from intravenous epoprostenol to intravenous treprostinil using a rapid switch protocol...
  65. doi request reprint [Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]
    Laurent Savale
    Universite Paris Sud, Faculte de Medecine, Le Kremlin Bicetre, France
    Presse Med 40:1S54-60. 2011
    ..Finally, clinical trials evaluating combinations of treatments have shown encouraging results...
  66. ncbi request reprint [Deep venous thrombosis and pulmonary embolism]
    Marc Humbert
    Service de Pneumologie et Reanimation Respiratoire, UPRES EA2705, Hopital Antoine Beclere, Universite Paris Sud, 92140 Clamart
    Rev Prat 52:555-64. 2002
  67. doi request reprint Pulmonary arterial hypertension and HIV infection
    Bruno Degano
    Service de Pneumologie, Hopital Antoine Beclere, 92141 Clamart, France
    Semin Respir Crit Care Med 30:440-7. 2009
    ..Other PAH therapies, including prostacyclin analogs, type 5 phosphodiesterase inhibitors, and single endothelin receptor antagonists, have yet to be evaluated in PAH-HIV...
  68. doi request reprint Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice
    Olivier Sitbon
    Service de Pneumologie, Hopital Antoine Beclere, Clamart, France
    Curr Opin Pulm Med 16:S21-6. 2010
    ..Treatment goals need to be carefully defined in order to correctly measure whether a treatment is successful and indicate when additional treatment is required...
  69. ncbi request reprint Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease
    Arnaud Resten
    Service de Radiologie, UPRES EA 2705 Maladies vasculaires pulmonaires, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, 157 rue de la Porte de Trivaux, Clamart 92140, France
    AJR Am J Roentgenol 183:65-70. 2004
    ..The aim of our study was to evaluate this disease noninvasively using CT of the chest...
  70. ncbi request reprint Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture
    Steeve Provencher
    Centre des Maladies Vasculaires Pulmonaires UP RES EA 2705, Service de Pneumologie et Reanimation Respiratoire, AP HP Université Paris Sud XI, Hopital Antoine Beclere, Clamart, France
    Chest 128:622S-628S. 2005
    ..Early detection and adequate clinical classification of the disease, better assessment of patients' prognosis, and improved therapeutic strategies are important challenges for clinicians in coming years...
  71. doi request reprint Drug-induced pulmonary arterial hypertension: a recent outbreak
    David Montani
    Universite Paris Sud, Le Kremlin Bicetre, France
    Eur Respir Rev 22:244-50. 2013
    ..PAH remains a rare complication of these drugs, suggesting possible individual susceptibility, and further studies are needed to identify patients at risk of drug-induced PAH. ..
  72. doi request reprint Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment
    Marie Camille Chaumais
    Universite Paris Sud, Faculte de Pharmacie, Chatenay Malabry, France
    Expert Opin Drug Metab Toxicol 9:1193-205. 2013
    ..Sildenafil citrate is a potent, selective phosphodiesterase type 5 inhibitor approved for the treatment of pulmonary arterial hypertension (PAH) and plays an important role in the management of the disease...
  73. doi request reprint Pulmonary hypertension in patients with neurofibromatosis type I
    David Montani
    Faculte de Medecine, Universite Paris Sud, Kremlin Bicetre, France
    Medicine (Baltimore) 90:201-11. 2011
    ..Further studies are needed to better understand the pathophysiology and the role, if any, of neurofibromin in NF1-associated PH...
  74. doi request reprint A hemodynamic study of pulmonary hypertension in sickle cell disease
    Florence Parent
    Universite Paris Sud, Kremlin Bicetre, Hopital Antoine Beclere, Clamart, France
    N Engl J Med 365:44-53. 2011
    ..The prevalence and characteristics of pulmonary hypertension in adults with sickle cell disease have not been clearly established...
  75. ncbi request reprint Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension
    David Montani
    Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Université Paris Sud 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Chest 131:101-8. 2007
    ..Endothelin (ET)-1 has been shown to play a significant pathogenic role in PAH. ET-3 has not yet been investigated in PAH...
  76. ncbi request reprint New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure
    Denis Chemla
    Service EFCR, Broca 7, Hopital de Bicetre, 78 Rue du Général Leclerc 94, 275 Le Kremlin Bicêtre Cedex, France
    Chest 126:1313-7. 2004
    ..We tested the hypothesis that the measurement of MPAP and SPAP is redundant in resting humans over a wide pressure range...
  77. ncbi request reprint Influence of donor characteristics on outcome after lung transplantation: a multicenter study
    Gabriel Thabut
    Division of Pulmonary Medicine, Beaujon Hospital, Clichy, France
    J Heart Lung Transplant 24:1347-53. 2005
    ..We aimed to determine, on a large cohort of patients, the effect of donors characteristics on short- and long-term outcome of lung transplantation..
  78. doi request reprint [Pulmonary arterial hypertension and sickle cell disease]
    Laurent Savale
    Universite Paris Sud, Faculte de Medecine, 94276 Kremlin Bicêtre, France
    Presse Med 42:338-46. 2013
    ..5m/s is used. At present, no specific treatments for pulmonary arterial hypertension is currently approved for the treatment of PAH associated with sickle cell disease due to lack of data in this specific population...
  79. ncbi request reprint Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases
    Marc Humbert
    Center for Pulmonary Vascular Diseases, Service de Pneumologie et Reanimation Respiratoire, Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Universite Paris Sud, France
    Nat Clin Pract Rheumatol 1:93-101. 2005
    ..This article reviews PAH associated with systemic rheumatic diseases and describes the role of ERAs in this setting...
  80. ncbi request reprint Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study
    Florence Parent
    Hopital Antoine Beclere, Assistance Publique Hopitaux de Paris, Clamart, France
    Thromb Res 120:195-200. 2007
    ..However, their role as an exclusionary first-line test is still uncertain, mainly because accuracy of the test varies according to the assay and the studied population...
  81. ncbi request reprint Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension
    Vincent Castelain
    Department of Pulmonary Medicine UPRES 2705, Antoine Béclère Teaching Hospital, Clamart, France
    Am J Respir Crit Care Med 165:338-40. 2002
    ..1 mm Hg/L/min/m(2) (p < 0.01). These results suggest that the improvement in exercise tolerance seen after 6 wk of prostacyclin therapy may be ascribable to a decrease in incremental pulmonary vascular resistance during exercise...
  82. ncbi request reprint Severe pulmonary arterial hypertension in type 1 glycogen storage disease
    Marc Humbert
    Service de Pneumologie, Centre des Maladies Vasculaires Pulmonaires, Hopital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France
    Eur J Pediatr 161:S93-6. 2002
    ....
  83. ncbi request reprint Serotonin transporter and receptors in various forms of human pulmonary hypertension
    Elisabeth Marcos
    INSERM U492 and Service de Physiologie Explorations Fonctionnelles, Creteil, Paris, France
    Chest 128:552S-553S. 2005
  84. ncbi request reprint Automatic quantification of right ventricular function with gated blood pool SPECT
    Doumit Daou
    Department of Nuclear Medicine, Lariboisiere University Hospital, AP HP, Paris, France
    J Nucl Cardiol 11:293-304. 2004
    ..In parallel, we compared the RVEF, RV end-diastolic volume (EDV), and RV end-systolic volume (ESV) provided by QBS and GBPS(35%)...
  85. doi request reprint Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma
    Hanadi Dib
    Inserm U1016, Institut Cochin, Paris, France
    Eur Respir J 39:1405-14. 2012
    ....
  86. ncbi request reprint CX(3)C chemokine fractalkine in pulmonary arterial hypertension
    Karl Balabanian
    INSERM U131, UPRES EA2705, Centre des Maladies Vasculaires Pulmonaires, Service de Pneumologie et Reanimation Respiratoire, Institut Paris Sud sur les Cytokines, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Am J Respir Crit Care Med 165:1419-25. 2002
    ..Fractalkine mRNA and protein product are expressed in pulmonary artery endothelial cells. We conclude that inflammatory mechanisms involving chemokine fractalkine and its receptor CX(3)CR1 may have a role in the natural history of PAH...
  87. ncbi request reprint [A new clinical classification of pulmonary hypertension]
    Gerald Simonneau
    Universite Paris Sud 11, UPRES EA 2705, Centre National de Référence de l Hypertension Artérielle Pulmonaire, Pneumologie et Réanimation respiratoire, Hopital Antoine Beclere, 157, rue de la Porte de Trivaux 92141 Clermont cedex, France
    Bull Acad Natl Med 193:1897-909. 2009
    ....
  88. ncbi request reprint Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension
    Rodney Hughes
    Pulmonary Vascular Diseases Unit, Papworth Hospital, Cambridgeshire, CB3 8RE, UK
    Expert Opin Pharmacother 7:1133-8. 2006
    ..This article examines the rationale for the use of the oral dual endothelin receptor antagonist bosentan in this life-threatening condition...
  89. ncbi request reprint Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Box C 272, 4200 E Ninth Ave, Denver, CO 80262, USA
    Chest 131:1917-28. 2007
    ..Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended...
  90. ncbi request reprint Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Rheumatol 34:2417-22. 2007
    ..The phosphodiesterase-5 inhibitor sildenafil citrate enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH. We examined the efficacy and safety of oral sildenafil in patients with PAH-CTD...
  91. ncbi request reprint [Guidelines on diagnosis and treatment of pulmonary arterial hypertension]
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Italy
    Rev Esp Cardiol 58:523-66. 2005
  92. ncbi request reprint Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Bologna, Italy
    J Am Coll Cardiol 39:1496-502. 2002
    ....
  93. ncbi request reprint Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension
    Elisabeth Marcos
    INSERM U492 and Service de Physiologie Explorations Fonctionnelles, Hôpital H Mondor, Creteil, France
    Circ Res 94:1263-70. 2004
    ..We conclude that 5-HTT overexpression is a common pathogenic mechanism in various forms of PH...
  94. ncbi request reprint Bosentan therapy for pulmonary arterial hypertension
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California at San Diego, La Jolla 92037 1330, USA
    N Engl J Med 346:896-903. 2002
    ..The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses...
  95. ncbi request reprint Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Italy
    J Am Coll Cardiol 41:1380-6. 2003
    ..The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH)...
  96. ncbi request reprint Inhaled iloprost for severe pulmonary hypertension
    Horst Olschewski
    Department of Internal Medicine II, University Clinic, Giessen, Germany
    N Engl J Med 347:322-9. 2002
    ..Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension...
  97. ncbi request reprint Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension
    David Langleben
    Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Am Heart J 143:E4. 2002
    ..Circulating mediators, including thromboxane A2, the vasoconstrictor, platelet aggregant, and smooth muscle mitogen, may contribute to the progression of vascular narrowing in primary pulmonary hypertension (PPH)...
  98. ncbi request reprint Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension
    Rajiv D Machado
    Division of Medical Genetics, Department of Genetics, University of Leicester, Leicester, United Kingdom
    Hum Mutat 27:121-32. 2006
    ....
  99. ncbi request reprint Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia
    Saadia Eddahibi
    INSERM U651, Departement de Physiologie, Hôpital H Mondor, AP HP, Creteil, France
    Circulation 113:1857-64. 2006
    ..We investigated the role of pulmonary microvascular endothelial cells (P-ECs) in controlling PA-SMC growth...
  100. ncbi request reprint Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension
    Laurence Dewachter
    INSERM U651, Faculte de Medecine, 8, rue Général Sarrail, Creteil, France
    Am J Respir Crit Care Med 174:1025-33. 2006
    ..Angiopoietins are involved in blood vessel maturation and remodeling...
  101. ncbi request reprint New treatments for pulmonary arterial hypertension
    Marius M Hoeper
    Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
    Am J Respir Crit Care Med 165:1209-16. 2002